Previous Blogs

Avatar

By Victoria Morgan

September 16, 2020

Have you thought about the complexities of a patient’s journey through treatment? Navigating from leukemia diagnosis to treatment can be a difficult one. Informing family members, managing loved ones’ reactions, weighing the many different treatment options and facing the reality of multiple hospital visits can be overwhelming.

Avatar

By Victoria Morgan

June 27, 2019

In 2018, we saw a record-setting year for new-molecular entity (NME) approvals (59) at the FDA1 versus 46 in 2017. 58% were for orphan drugs (patient population less than 200,000 in the US) with 17 biologic-based NME’s. Biosimilars are gaining traction in Europe, in particular. Major factors that are driving the market growth are next-generation business, high growth in chronic diseases, less expensive biosimilar drugs and favorable government regulations.

Avatar

By Victoria Morgan

May 07, 2019

Before an injectable biologic can be formulated and manufactured, an extensive series of pre-formulation checks are necessary to ensure that developers avoid formulating an unstable, non-viable product¹. Developers must determine whether the injectable biologic will break down within the intended formulation or the manufacturing process. The drug must be thermally stable, possibly resistant to oxidation, tolerate variations in light, and other environmental stresses placed on it during manufacturing and packaging.